logo

Stock Screener

Forex Screener

Crypto Screener

VVOS

Vivos Therapeutics, Inc. (VVOS)

$

5.17

+0.74 (14.31%)


Key metrics

Financial statements

Free cash flow per share

Free cash flow per share

-1.6271

Market cap

Market cap

26.1 Million

Price to sales ratio

Price to sales ratio

1.7836

Debt to equity

Debt to equity

0.3174

Current ratio

Current ratio

0.7673

Income quality

Income quality

1.2432

Average inventory

Average inventory

0

ROE

ROE

-1.7043



Technology

Technology

Technology – consumer electronics

Largecap

Largecap

With a market cap of 121,78 bil stock is ranked 1

Low risk

Low risk

ISS score of this stock is ranked 1


Company description

Profile

Vivos Therapeutics, Inc. is a medical technology company that focuses on developing and commercializing innovative treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. The fiscal year 2024 financial data reflects a net total of other income and expenses of $35,000.00 which encompasses non-core financial activities. The company's operational profitability is denoted by an operating income ratio of -0.74 highlighting its ability to generate earnings from its core business activities. Shareholders can gauge profitability on an individual basis, as indicated by the earnings per share (EPS) of -$1.68. Furthermore, the company incurred an income tax expense of $0.00 demonstrating its tax obligations as part of its business operations. Based in Highlands Ranch, Colorado, and founded in 2016, Vivos Therapeutics offers the Vivos System, a non-invasive, non-surgical, and non-pharmaceutical multi-disciplinary treatment modality aimed at providing solutions for dentofacial abnormalities, OSA, and snoring. Additionally, the company provides the VivoScore Program, which includes screening and home sleep testing for both adults and children, and primarily markets its offerings to licensed professionals, with a focus on general dentists in the United States and Canada. The company operates within the Healthcare sector, where it is recognized as a key player in the Medical - Devices industry, making significant contributions to the overall market landscape. Currently, the stock is affordable at $5.17 making it an appealing option for budget-conscious investors. However, it should be noted that the stock has a low average trading volume of 673,753.00 indicating lower market activity. With a market capitalization of $30,448,818.00 Vivos Therapeutics is classified as a small-cap player, reflecting its position within the industry. The company's commitment to driving innovation and growth showcases its potential impact on the sector, as it continues to address critical healthcare needs through its advanced treatment solutions.

What is Vivos Therapeutics, Inc. (VVOS)'s current stock price?

The current stock price of Vivos Therapeutics, Inc. (VVOS) is $5.17 as of 2025-07-07. Prices may fluctuate during the trading day. For real-time updates, check your brokerage platform or financial news websites.

Investing in Vivos Therapeutics, Inc. (VVOS) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bullish outlook. Always conduct your own research before investing.

Analysts predict Vivos Therapeutics, Inc. stock to fluctuate between $1.97 (low) and $6.28 (high) in the next 365 days, reflecting market expectations and potential volatility.

As of 2025-07-07, Vivos Therapeutics, Inc.'s market cap is $30,448,818, based on 5,889,520 outstanding shares.

Compared to Meta Platforms, Inc. Class A Common Stock, Vivos Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.

To buy Vivos Therapeutics, Inc. (VVOS) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for VVOS. Place an order (Market, Limit, etc.).

The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.

Vivos Therapeutics, Inc.'s last stock split was 1:25 on 2023-10-27.

Revenue: $15,031,000 | EPS: -$1.68 | Growth: -84.92%.

Visit https://vivos.com/investor-relations for detailed financial reports.

You can explore historical data from here

All-time high: $271.49 (2021-04-12) | All-time low: $1.91 (2024-05-30).

Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.


News

VVOS

globenewswire.com

13 days ago

New Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in Children

LITTLETON, Colo., June 26, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leader in proprietary, non-invasive treatments for obstructive sleep apnea (OSA), today announced that the European Journal of Pediatrics has published the results of a groundbreaking multicenter clinical trial evidencing positive results for the treatment of OSA in children using Vivos' patented Daytime-Nighttime Appliance (DNA).

VVOS

seekingalpha.com

2 months ago

Vivos Therapeutics, Inc. (VVOS) Q1 2025 Earnings Call Transcript

Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q1 2025 Earnings Conference Call May 15, 2025 5:00 PM ET Company Participants Brad Amman - CFO Kirk Huntsman - Chairman and CEO Conference Call Participants Do Kim - Water Tower Research Lucas Ward - Ascendiant Capital Markets Operator Good day, everyone. And welcome to the Vivos Therapeutics First Quarter 2025 Earnings Call.

VVOS

zacks.com

2 months ago

Vivos Therapeutics, Inc. (VVOS) Reports Q1 Loss, Lags Revenue Estimates

Vivos Therapeutics, Inc. (VVOS) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $1.63 per share a year ago.

VVOS

globenewswire.com

2 months ago

Vivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference Call

LITTLETON, Colo., May 14, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring in adults and moderate to severe OSA in children ages 6 – 17)), today announced it plans to release its first quarter 2025 financial results after market close on Thursday, May 15, 2025.

VVOS

zacks.com

2 months ago

Vivos Therapeutics, Inc. (VVOS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Vivos Therapeutics (VVOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

VVOS

globenewswire.com

3 months ago

Vivos Therapeutics Signs Definitive Agreement to Acquire Largest Sleep Center Operator in Nevada

By acquiring The Sleep Center of Nevada, Vivos expands its business model to make its OSA treatments available to thousands of patients in the greater Las Vegas metro area Acquisition expected to close later this quarter or in the third quarter LITTLETON, Colo., April 16, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leader in proprietary, non-invasive treatments for obstructive sleep apnea (OSA), today announced a definitive agreement to acquire the operating assets of The Sleep Center of Nevada (“SCN”), the largest operator of medical sleep centers in Nevada.

VVOS

seekingalpha.com

3 months ago

Vivos Therapeutics, Inc. (VVOS) Q4 2024 Earnings Call Transcript

Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q4 2024 Earnings Conference Call March 31, 2025 5:00 PM ET Company Participants Bradford Amman - CFO, Treasurer & Secretary Kirk Huntsman - Co-Founder, Chairman & CEO Conference Call Participants Guyn Kim - Water Tower Research Scott Henry - Alliance Global Partners Lucas Ward - Ascendiant Capital Markets Operator Good day, everyone, and welcome to the Vivos Therapeutics Full Year 2024 Earnings Conference Call. [Operator Instructions] This conference call is being recorded, and a replay of today's call will be available on the Investor Relations section of Vivos' website and will remain posted there for the next 30 days.

VVOS

zacks.com

3 months ago

Vivos Therapeutics, Inc. (VVOS) Reports Q4 Loss, Lags Revenue Estimates

Vivos Therapeutics, Inc. (VVOS) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $3.05 per share a year ago.

VVOS

globenewswire.com

3 months ago

Vivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update

Year over year product revenue increased 26% Operating expenses declined 21% and year over year operating loss decreased 35% Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., March 31, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA in adults) and moderate to severe OSA in children ages 6 - 17), today reported financial results and operating highlights for the full year ended December 31, 2024.

VVOS

globenewswire.com

3 months ago

Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call

LITTLETON, Colo., March 28, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring in adults and moderate to severe OSA in children ages 6 – 17), today announced it plans to release its full year 2024 financial results after market close on Monday, March 31, 2025.

See all news

logo
Stocks, Indicators, Pattern screeners all at one place
Stock Screener
Forex Screener
Crypto Screener